Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering-Plough Asmanex

Executive Summary

Dose counter mechanism for mometasone furoate dry powder inhaler "has not been proven to be accurate or reliable," Jan. 19 FDA 483 inspection report states. Manual counts did not match the numbers displayed by the inhaler device's counter, FDA observed. The counting mechanism also exhibited "jamming" and would not decrement as intended. The once-daily corticosteroid has been "approvable" since October 1999 for treatment of asthma in patients 12 and older. The 483 was released by Public Citizen March 1 (1see related story, p. 6)

You may also be interested in...



Schering/FDA Relations Are Priority For Hassan: GMPs, Asmanex On Agenda

Schering-Plough CEO Fred Hassan hopes his credibility with FDA can help in discussions over the company's GMP work plan and the delayed Asmanex approval

Schering/FDA Relations Are Priority For Hassan: GMPs, Asmanex On Agenda

Schering-Plough CEO Fred Hassan hopes his credibility with FDA can help in discussions over the company's GMP work plan and the delayed Asmanex approval

Schering Claritin, Rebetol Await FDA Certification After Consent Decree

Schering-Plough's first batch of products submitted to FDA for certification under a May 16 consent decree will include the Claritin 10 mg dose and the antiviral Rebetol

Related Content

UsernamePublicRestriction

Register

PS037448

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel